Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.

Slides:



Advertisements
Similar presentations
Marta José, Instituto Grifols S.A., Barcelona, SPAIN
Advertisements

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.
Replacement of the 1 st Parvovirus B19 DNA International Standard SoGAT XXI, Brussels, 28th-29th May 2009 Sally Baylis.
A PROSPECTIVE STUDY OF POLYMERASE CHAIN REACTION TESTING ON POOLED PLASMA VS. INDIVIDUAL DONATION HIV P24 TESTING.
Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.
The Sense of Sensitivity I Dr. Matthias Gessner Plasma Control Europe/Plasma Analytics Baxter AG, Vienna.
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.
Paris, May 2004SoGAT XVII SoGAT and the Development of Standards Harvey Holmes Division of Retrovirology NIBSC, UK.
Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:
Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA
XVIII SoGAT Washington 24 May 2005 SoGAT and HIV NAT Standards - 2 nd International Standard for HIV-1 RNA Harvey Holmes*, Clare Davis* and Alan Heath**
HIV Testing CDC power point edited by M. Myers
PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.
Generic Automated Sample Preparation for Commercial NAT Assays
E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.
BioLife Plasma Services Experience with HBV NAT Testing
HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.
Poor Reproducibility of HIV­1 Low-level Viraemia Results with 3 Commercial Real-time PCR Assays Jean Ruelle 1, Laurent Debaisieux 2, Ellen Vancutsem 3,
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
DEVELOPMENT OF THE TOOLS FOR PCR-DETECTION OF HEPATITIS A AND C VIRUSES IN INTRAHOSPITAL VIRAL CONTAMINATION RESEARCH. 1 D. I. Ivanovsky Virology Institute,
Update on the Replacement of the HCV RNA International Standard Sally Baylis & Alan Heath, NIBSC SoGAT XX, Warsaw June 2007.
SOGAT Validation of HCV-RNA detection in small test pools on cadaveric samples Marco Koppelman #, Theo Cuypers #, Mirjam de Waal #, Maarten.
Clinicaloptions.com/hepatitis Serum HBsAg as a Predictor of Response to PegIFN in HBeAg-Positive Patients Slideset on: Chan HL, Wong VW, Chim AM, Chan.
HIV Cellular Pathogenesis III
E A 1 Parvovirus B19 and HAV Screening of Whole Blood Donations SL Stramer, KL Kane, ML Beyers, RY Dodd, American Red Cross and RIF Smith, National.
Occult hepatitis B virus (HBV) and hepatitis C virus (HCV) viremia in women with and at-risk for HIV/AIDS Taylor L, Gholam P, Delong A, Rompalo A, Klein.
Standardisation of P. falciparum HBV, HCV and NAT Sally Baylis, NIBSC SoGAT XVIII.
Parvovirus B19 Genotype 2 Plasma, Sourced from the US Dr Sally A. Baylis, Division of Virology NIBSC.
Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.
SoGAT XVII/Paris, 2004 Proficiency Testing of In-House Developed HIV-1 NAT for Blood Screening Michael Chudy, Paul-Ehrlich-Institut Division of Virology,
Xenotropic Murine Leukemia Virus-Related Retrovirus: CCR Assay Development.
SoGAT June 14, 2006 HCV-RNA and HIV-RNA detection in small test pools of cadaveric samples for viral safety of tissue transplants Maarten Koot#,
The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.
LOWERING THE DETECTION LIMITS OF HIV-1 VIRAL LOAD USING REAL-TIME IMMUNO-PCR FOR HIV-1 P24 ANTIGEN Niel T. Constantine, Ph.D., Daniel Edelman, M.S., Janet.
Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
SoGAT, Berne 2006BTS SRC Berne Ltd. Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd. Dr. Martin Stolz.
History of ILC Involvement in NAT Standardization 1998: Inter-Organization Discussion for the Establishment of Standard Reference Material for Nucleic.
W W W. Q I A G E N. C O M Dirk Heckel, PhD Diagnostic Sample Preparation and Stabilization QIAGEN GmbH.
Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.
A multi-centre NAT evaluation study of run and trend control samples Harry van Drimmelen 1, Joe O’Donnellan 2, Rene Bax 1, Henrik Ullum 3 and the Danish.
Evaluation of the Presage™ ST2 ELISA Jun Lu 1, David G. Grenache 1,2 1 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 2 Department.
NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.
Preparation of HBV DNA reference standards and the experience of HBV NAT in Taiwan Dr. Hwei-Fang Cheng Department of Health, Taiwan.
An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.
DRK-Blutspendedienst West  nPrecipitation steps (PEG), centrifugation and careful resuspension of the invisible pelleted viral particles precede efficient.
Phar. Nhat Mang/ Roche Vietnam
SoGAT May 2005 Are conversion factors to international units assay related? Marco Koppelman, Henk Reesink, Nico Lelie, Theo Cuypers.
 Routine viral diagnostics: indirect and direct detection of viruses. ◦ Indirect detection: serological tests; ◦ Direct detection:  Viral antigens;
Progress on Study to Validate Synthetic Materials for Use as Calibrators and References SoGAT XIX Bern, 14 June 2006 Roberta M. Madej Roche Molecular Diagnostics.
Relative Sensitivities of US Licensed NAT Assays for Detection of Viremia in Early HIV and HCV Infection MP Busch, SA Glynn, DJ Wright, D Hirschkorn, ME.
Date of download: 6/3/2016 From: Assessment of Hepatitis C Viremia Using Molecular Amplification Technologies: Correlations and Clinical Implications Ann.
HBV viral load 측정 및 임상적 의의 진단검사의학과이희주 Content v 임상적 의의 v 측정법.
HBV DNA Quantification: Results from the UK NEQAS Proficiency Panel
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Saeko Mizusawa, Yoshiaki Okada
Experience in Testing of Genotypes of B19
GRIFOLS PLASMA: genotype 2 vB19 sample
Harvey Holmes, Clare Morris and Neil Berry Division of Retrovirology
Performance Characteristics of a Quantitative, Homogeneous TaqMan RT-PCR Test for HCV RNA  Joerg Kleiber, Thomas Walter, Gerd Haberhausen, Sue Tsang,
Diagnosis and Point of Care Testing of Hepatitis C
Evaluation data on the new Roche cobas s 201 system with the cobas TaqScreen MPX test Lutz Pichl, Volkmar Schottstedt German Red Cross Blood Transfusion.
Evaluation of Candidate Standard XX (97/650)
K.H. Buchheit, A. Daas, C.M. Nübling, J.M. Spieser 3 July 2003
Italian EQA study for HCV RNA, HIV RNA and HBV DNA G. M. Bisso, K
1st International Standard for HIV-1 RNA NIBSC Code 97/656
Performance Characteristics of a Quantitative, Homogeneous TaqMan RT-PCR Test for HCV RNA  Joerg Kleiber, Thomas Walter, Gerd Haberhausen, Sue Tsang,
Evaluation of the Abbott Investigational Use Only RealTime HIV-1 Assay and Comparison to the Roche Amplicor HIV-1 Monitor Test, Version 1.5  Michael T.
SoGAT meeting XXI May (2009), Brussels, Belgium
Presentation transcript:

Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto Grifols S.A., Barcelona, SPAIN SoGAT XVIII, Washington May 2005

Importance of the stability of nucleic acids in stored plasma samples To avoid any false negative before testing a contaminated sample, especially in low-titer samples. To minimise logistic problems during long term storage (-70 ºC vs -20 ºC) of retained samples. To minimise logistic problems due to the shipping conditions. To monitor the viral loads by quantitative assays in the performance of antiviral therapy, as well as in the evolution of the infection.

SoGAT XVIII, Washington May 2005 Stability of nucleic acids in stored plasma samples: previous data (José et al, Biologicals 2003; 31: 1-8) We demonstrated that no advantage was derived from storing samples containing different HCV RNA concentrations at -70 ºC vs -20 ºC: Absence of decay attributable to the storage at -20 ºC during the period studied ( years) in samples with high HCV RNA titer. Absence of significant titer decay at -20 ºC for approximately 1 year of study at intermediate concentrations (half-life between 231 and 261 days). In samples containing low levels of HCV RNA (100 IU/ml) no loss of reactivity was detected during the storage at -20 ºC for approximately 3.5 years. The half-life of a HCV sample diluted to 10 4 IU/ml and 10 5 IU/ml and stored at 5 ºC and 25 ºC was nearly 3 months and 14 days, respectively. The aim of the present study was:  To update the stability study results of samples containing low levels of HCV RNA  To evaluate the RNA and DNA stability of HIV-1 and HBV, stored at different temperatures

Stability of low level HCV RNA in samples under freezing conditions A HCV RNA-positive sample was diluted in cryosupernatant to approximately 100 IU/ml. The sample was aliquoted and stored at ≤ -20 ºC and ≤ -70 ºC. After different storage periods, different dilutions of samples were analysed by RT-PCR in triplicate. The samples were analysed using an in-house qualitative RT-PCR (95 % detection limit was established at 21 IU/ml by Probit analysis). SoGAT XVIII, Washington May 2005 Study design: José et al, Biologicals 2005; 33: 9-16 *2 positives from a total of 2 (1 test failed) Positive results out of 3 replicates  - 20 ºC  - 70 ºC Dilution Series Time, Days Neat 1/2 1/4 1/8 Neat1/2 1/4 1/ * (5 years) TOTAL 80/81 76/81 72/81 57/81 76/80 76/81 73/81 63/81 Results I:

Stability of low level HCV RNA in samples under freezing conditions: Results II TIME, years Positive results for all dilutions ≤ -20 ºC≤ -70 ºC 5285/324288/323 José et al, Biologicals 2005; 33: 9-16 SoGAT XVIII, Washington May 2005

Stability of HIV-1 RNA in samples under freezing conditions (-70 ºC vs -20 ºC) SoGAT XVIII, Washington May 2005 Results: The NIBSC HIV-1 RNA W.R. PWS-1 (code 99/634) was diluted in a negative plasma pool at approximately 1000 IU/ml. The sample was aliquoted and stored at ≤ -20 ºC and ≤ -70 ºC. After different storage periods, different dilutions of samples were analysed by RT-PCR in duplicate. The samples were analysed using an in-house qualitative RT-PCR (95 % detection limit was established at 237 IU/ml by Probit analysis). Study design: José et al, Biologicals 2005; 33: 9-16

TIME, years Positive results for all dilutions ≤ -20 ºC≤ -70 ºC 340/5444/54 Stability of HIV-1 RNA in samples under freezing conditions (-70 ºC vs -20 ºC): Results II José et al, Biologicals 2005; 33: 9-16 SoGAT XVIII, Washington May 2005

Stability of HIV-1 RNA and HBV DNA in samples stored at 5 ± 3 °C and RT: Study Design The NIBSC HIV-1 RNA W.R. PWS-2 (code 97/632) and the WHO HBV DNA I.S. (code 97/746) were diluted in a negative plasma pool to approximately 10 3 IU/ml and 10 4 IU/ml. The samples were aliquoted and stored at 5±3 ºC and 25±2 ºC. After different storage periods (between 0 and 28 days), the samples were quantified by PCR using: Amplicor HIV-1 Monitor and/or the ultra sensitive Amplicor HIV-1 Monitor from Roche (quantitation limit, 500 c/ml and 50 c/ml, respectively). Amplicor HBV Monitor from Roche (quantitation limit 200 c/ml). The HIV-1 RNA and HBV DNA titer decay was analysed by: Linear regression against time. The half-life (t 1/2 ) decay of each sample under different storage conditions. SoGAT XVIII, Washington May 2005 José et al, Biologicals 2005; 33: 9-16

Stability of HIV-1 RNA in samples stored at 5 ± 3 °C and RT: Results Regression Analysis (log titer versus time) 5 ºC25 ºC SAMPLE10 4 IU/ml10 3 IU/ml10 4 IU/ml Slope, days p-value to test significance of decay t 1/2, days a n.a IU/ml (2.72 log 10 c/ml) 10 4 IU/ml (3.99 log 10 c/ml) RT (25 ºC) SoGAT XVIII, Washington May 2005 José et al, Biologicals 2005; 33: 9-16 n.a., not applicable (no decay) a, Half-life expressed to arithmetical scale (i.e.: 50 % or 0.3 log titer reduction) IU/ml (2.72 log 10 c/ml) 10 4 IU/ml (3.99 log 10 c/ml) Cold-room (5 ºC)

Stability of HBV DNA in samples stored at 5 ± 3 °C and RT: Results Regression Analysis (log titer versus time) 5 ºC25 ºC SAMPLE10 4 IU/ml10 3 IU/ml10 4 IU/ml10 3 IU/ml Slope, days p-value to test significance of decay IU/ml (3.56 log 10 c/ml) 10 4 IU/ml (4.51 log 10 c/ml) RT (25 ºC) 10 3 IU/ml (3.56 log 10 c/ml) 10 4 IU/ml (4.51 log 10 c/ml) Cold-room (5 ºC) SoGAT XVIII, Washington May 2005 José et al, Biologicals 2005; 33: 9-16

Stability of HCV, HIV-1 and HBV in stored plasma samples: Conclusions I A sample containing 100 IU/ml HCV RNA will remain RT-PCR reactive after at least 5 years of storage, either at -20 ºC or at -70 ºC. No differences between -70 ºC and -20 ºC are evidenced up to date. SoGAT XVIII, Washington May 2005 José et al, Biologicals 2005; 33: 9-16

Stability of HCV, HIV-1 and HBV in stored plasma samples: Conclusions II For HIV-RNA : A sample containing 1000 IU/ml HIV-1 RNA will remain RT-PCR reactive after at least 3 years, either at -20 ºC or at -70 ºC. No differences between -70 ºC and -20 ºC are evidenced up to date. Absence of decay in HIV-1 RNA caused by storage at 5 ºC during the period studied (28 days for the sample of 10 4 IU/ml and 14 days for the sample of 10 3 IU/ml). The HIV-1 RNA sample of 10 4 IU/ml, stored at 25 ºC, showed a half-life (0.3 log 10 of titer reduction) of nearly 7 days. After 7 days of storage of the sample with 10 3 IU/ml of HIV-1 RNA, at 25 ºC, the titer reduction was lower than 0.3 log 10 (0.26 log 10 ), which can be considered non-relevant. After 28 days of storage at 5 ºC or at 25 ºC, no decay of HBV DNA titer was observed, neither at 10 4 IU/ml, nor at 10 3 IU/ml. The nucleic acids of viruses, in terms of NAT reactivity, appear to be very stable under a wide range of storage conditions. SoGAT XVIII, Washington May 2005 José et al, Biologicals 2005; 33: 9-16